DMRA Damora Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1800315 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-1,741.0%
TTM EPS YoY179.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-116.1%
ROA-107.4%
ROIC (approx.)-331.3%
Asset turnover—
Leverage & solvency
Liabilities / assets6.9%
Debt / equity0.00x
Current ratio14.80x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.20x
Accruals ratio-85.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $26.88M | $6.40M | $23.77M | $48.21M | $38.49M |
| SG&A expense | $9.69M | $10.50M | $12.69M | $13.00M | $13.74M |
| Operating income | -$210.87M | -$22.26M | -$39.91M | -$61.21M | -$52.23M |
| Pretax income | -$209.79M | -$21.40M | -$38.35M | -$61.62M | -$51.75M |
| Income tax | $50,000 | $41,000 | $0 | $0 | $0 |
| Net income | -$209.84M | -$21.44M | -$38.35M | -$61.62M | -$51.75M |
| EBITDA | -$210.85M | -$22.24M | -$39.64M | -$61.16M | -$52.21M |
| EPS (basic) | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 |
| EPS (diluted) | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 |
| Dividends declared per share | 0.00 | 0.00 | — | — | 0.00 |
| Weighted avg. shares (diluted) | 1.36M | 1.16M | 1.06M | 25.41M | 25.26M |
| Banking | |||||
| Net interest income | $1.17M | $844,000 | $1.69M | $722,000 | $156,000 |
| Balance sheet | |||||
| Cash & equivalents | $257.62M | $14.18M | $21.46M | $32.79M | $62.56M |
| Short-term investments | $0 | — | $11.69M | $27.44M | $37.63M |
| Current assets | $260.42M | $16.84M | $36.77M | $63.91M | $110.10M |
| PP&E, net | $36,000 | $57,000 | $78,000 | $357,000 | $203,000 |
| Total assets | $260.53M | $17.13M | $38.23M | $73.19M | $122.22M |
| Current liabilities | $20.07M | $1.20M | $5.83M | $11.11M | $4.54M |
| Total liabilities | $20.15M | $1.30M | $5.90M | $11.44M | $4.99M |
| Shareholders' equity | $239.04M | $14.47M | $32.33M | $61.75M | $117.22M |
| Shares outstanding | 1.60M | 1.32M | 1.08M | 25.65M | 25.26M |
| Cash flow statement | |||||
| Operating cash flow | -$6.73M | -$18.62M | -$36.91M | -$42.93M | -$52.31M |
| Capital expenditure | — | — | — | $196,000 | $223,000 |
| Free cash flow | — | — | — | -$43.13M | -$52.53M |
| Investing cash flow | -$17.37M | $11.65M | $22.33M | $12.38M | -$48.05M |
| Financing cash flow | $266.84M | — | $2.88M | $507,000 | — |
| Depreciation & amortization | $22,000 | $21,000 | $269,000 | $42,000 | $20,000 |
| Stock-based compensation | $998,000 | $3.24M | $5.43M | $5.57M | $4.48M |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.